NYSE:SYK

Stryker Corp. (SYK)

339.21
-1.88 (0.55%)
as of Aug 14, 2026, 8:00:00 pm Market Open.
260 watching
0
Investor Insights
star iconAug 15, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Stryker Corp. (SYK) remains a leading player in the medical device sector, particularly in orthopedics, holding a significant market share in the U.S. With its robust robotics platform and the increasing demand driven by aging demographics, particularly in hip and knee replacements, the company shows strong potential for recovery from recent challenges, including a cybersecurity attack. Despite recent weaknesses in the broader medtech industry, many analysts express optimism around SYK's growth trajectory, with expectations of revenue and earnings per share advancing in the coming years. Additionally, Stryker's solid relationships with healthcare providers and a sticky business model (where surgeons tend to stick with suppliers) position it well for sustained success. However, some experts caution that while the stock may have long-term merits, the current investment climate may not be optimal.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
ZIM, ZIM
BUY ON WEAKNESS

A great medical equipment company. Over time, they've consolidated and grown. Demographic trends are on his side. But he owns Abbott instead; you can't own everything. Wait for more of a pullback to buy. If the PE falls to the low-$20s, step in.

TOP PICK

A manufacturer of medical and surgical devices. The company has had positive sales growth for over 40 years. They do a great job at identifying areas where they are weak, finding a way to fill that gap and executing the strategy quickly. There is not much exposure they hold in China -- fortuitous right now. Yield 1.03% (Analysts’ price target is $232.92)

TOP PICK
A good acquirer and integrator and have a good position in hip and knee replacement. They're aiming for 1,000 robotic installations worldwide, now at 850. They took a drop in their last purchase but they've bounced back. (Analysts’ price target is $232.92)
COMMENT

Investing in healthcare is hard. He holds BDX which he sees it as the shopping mall of healthcare products. He used to own ZBH but they suffered from recalls. He would probably stick to one of the three since he believes they are the best run companies in healthcare.

BUY
Medical devices are a good play on aging US demographics. SYK recently merged with a smaller company to consolidate their hips and knees products. He owns its peers including Boston Scientific, but the whole space is enjoying a nice upside. You can buy SYK.
BUY
Joint replacements. Medical instruments. Great company. Issues with latest acquisition, so stock fell below its high.
COMMENT

SYK vs. Anthem He likes both. Stryker trades at 23x PE. He owns Anthem, which hit on earnings, but the market was skittish on their expense line. It's a great healthcare company

PAST TOP PICK
(A Top Pick Jan 04/19, Up 21%) The best, most innovative medical device company around. It's come off its highs recently as it acquired a spinal business, but it has room to run. It's long grown its earnings for many years. They excel at buying small companies specializing in hips, knees and spines.
TOP PICK
A diversified medical devices company. They create a variety of equipment, including orthopaedics and robotic surgery. The company has executed very well. They recently made an acquisition that helps them move into hips, knees and ankles. There is volatility. He would enter around $205-210. (Analysts’ price target is $230.25)
TOP PICK
Good demographic growth--people are getting older and need hip and knee replacement. They just bought a company that will make SYK the biggest company serving hands and ankles. Another plus is that doctors tend to stick with the same medical product manufacturers. They have $3 billion in free cash and pays a nice dividend. They constantly buy companies, but their debt is fine. (Analysts’ price target is $231.08)
DON'T BUY

SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.

BUY
Diversified in orthopedics and medical instruments. Zimmer falling on hard times has been to its benefit. Not that expensive, around 20x earnings. Likes it.
PAST TOP PICK
(A Top Pick Nov 20/18, Up 22%) Demographically, in a great spot. Recent acquisition will expand their market. Developing robotics. Positive long-term.
BUY
They don't have the patent cliffs that the drugs are going to come off, and they will continue to innovate. Aging demographics will help demand. He's happy to hold this.
BUY
One of his favourite medtech names. They lead in robotic surgery. Great organic growth. They're setting up for a great quarter.
Showing 91 to 105 of 174 entries